pulmonary arterial hypertension

Aviptadil Acetate's Potential in Pulmonary Arterial Hypertension

Aviptadil acetate, a synthetic 28-amino-acid version of vasoactive intestinal peptide, shows promise for treating pulmonary arterial hypertension through inhalation. Studies report benefits like reduced pulmonary artery pressure, increased cardiac output, and improved walk tests in patients. Experimental work links VIP deficiency to PAH development in mice, supporting further evaluation of this compound.